Eli Lilly’s lawsuit against Mochi Health has never really been just about Mochi. It is one piece of a much larger effort by Lilly to tighten the walls around tirzepatide, using litigation, regulatory pressure, advertising claims and challenges to the business models that have allowed non-branded versions of the drug to reach patients outside the traditi…